Jury still out on Sarepta’s next generation
The group’s lead next-gen exon skipper beats a low bar set by Exondys, but adverse events loom large.
Adverum halt raises more gene therapy questions
A serious adverse event puts ADVM-022’s future in doubt, and it could hurt other eye disease gene therapy players too.
Aldeyra eyes the future
A pivotal hit in allergic conjunctivitis could also bode well for upcoming readouts in the bigger indication of dry eye disease.
Bristol’s Tyk2 ticks the boxes
Bristol’s new oral psoriasis option looks much better than Otezla, but competing against injectables could be tricky.
The retreat of corporate venture funding?
Many corporate-backed funds remain enthusiastic venture investors, but some might be hitting the brakes.
